---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-013664"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2024-10-25T23:59:59+00:00"
generated_at: "2026-05-30T09:55:45.564612+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Protalix to present Phase I PRX-115 data in late-breaking poster at ACR Convergence 2024

## Summary
- PRX-115 is a recombinant PEGylated uricase for uncontrolled gout treatment.
- Data from Phase I trial will be presented at ACR Convergence 2024 (Nov 14-19, Washington, D.C.).
- Poster session: Monday Nov 18, 10:30 AM-12:30 PM EST; abstract number L05.
- Abstract available on ACR abstracts website; poster to be posted on Protalix website.
- No clinical results disclosed; presentation details only.

## SEC filing metadata
- accession: 0001558370-24-013664
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2024-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837024013664/0001558370-24-013664-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837024013664/plx-20241025x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-013664
- JSON: https://secwatch.observer/filing/0001558370-24-013664.json
- Plain text: https://secwatch.observer/filing/0001558370-24-013664.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.